| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10484958 | Value in Health | 2014 | 10 Pages |
Abstract
The ZSD-RSP strategy was most cost-effective at a willingness-to-pay threshold between $5,200 and $542,500 per QALY. Our results should be interpreted with caution because they are based largely on the CATIE trial with potentially limited generalizability to all patient populations and doses of SGAs used in practice.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Taehwan MS Pharm, PhD, Karen M. ScD,